- Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine
Jae-Cheol Jo et al, 2017, Annals of Hematology CrossRef - Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)
Therasa Kim et al, 2018, BMC Cancer CrossRef - GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL
Yasuo Takashima et al, 2020, Scientific Reports CrossRef - Analysis of genomic alterations in primary central nervous system lymphoma
Xin He et al, 2023, Medicine CrossRef - Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
Ted W. Johnson et al, 2014, Journal of Medicinal Chemistry CrossRef - The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma
Yuko Miyasato et al, 2018, Journal of Clinical and Experimental Hematopathology CrossRef